INTERIM REPORT 2nd QUARTER 2013

Q2

Letter from the Management Board

Dear Shareholders,

The first half of the year was disappointing for Alphaform. In the first quarter, business development was below our expectations, particularly in the Medical Division. The second quarter started with a modest April, this time in the 3D Printing and Additive Manufacturing business area. In view of the economic forecasts, which were now more positive again, and important special topics like the IAA, we were confident that the situation would brighten considerably over the course of the year. When in mid-June the similarly weak May figures were announced, we initially assumed that there were inventory problems, as the capacity utilisation of the companies contradicted the earnings development. When it came to the half-year inventory, we determined that declining prices were the main cause for the deterioration of earnings. We were aware of this effect in some projects – particularly in the case of master contracts – but in our high-speed 3D printing business with thousands of small orders, it is extremely difficult to draw conclusions about the impact of price effects on the company as a whole. The economic downturn in the fourth quarter of 2012 caused falling prices throughout the entire first quarter – this can happen quickly both upwards and downwards in our industry. As we were still in part working on orders from the previous year in the first quarter, the effect did not immediately emerge at full force. Overall, we now expect a price slump of around 10% over all business areas.

The situation has improved considerably since May, and incoming orders have actually been very satisfactory since the beginning of June. However, the generally declining economy makes it difficult to predict future development. Demand for laser-sintered products has risen clearly in recent months. We believe this trend is stable, and we therefore started up additional machines in June. At the same time, the entirety of production in the 3D Printing and Additive Manufacturing Division at Feldkirchen was restructured; the costs incurred, amounting to €0.25 million, were posted in the second quarter. If the present upward trend continues, we will expand our range of machinery even further. In addition, we have initiated improvements to our production efficiency with optimised use of materials and automated processes.

Counteracting overhead costs was possible only to a limited extent, as the facilities were well utilised and reduction of capacity was barely feasible. In addition, we wanted to keep hold of our employees, as we have many new programmes in the pipeline in the next one to two years. We are currently attempting to deploy our core team as flexibly as possible, for example with temporary work models.

The course of business in July was clearly positive again, especially in the 3D Printing and Additive Manufacturing Division. We have important trade fairs coming up over the rest of the year, which have always had a positive influence on our business in the past. In addition, we are preparing programmes in both the 3D Printing and Additive Manufacturing and Medical Divisions that are intended to reduce the cyclical dependence of our business model; we are expecting initial effects in the course of the second half of the year. In view of the good outlook at present, we expect to compensate largely for the loss-making first half by the end of the financial year.

Yours,

Dr Thomas Vetter

Alphaform in H1 2013: The economic trough takes effect

The key figures for the first half of the 2013 financial year are as follows:

- At €6.0 million, revenue in the second quarter of 2013 was 17.6% lower than the revenue of €7.3 million in the same quarter of the previous year and 9.1% lower than the revenue of €6.6 million in the first quarter of 2013. For the period between 1 January and 30 June, revenue fell by 10.5% from €14.1 million in 2012 to €12.6 million in 2013.

- As of 30 June 2013, booked business in the Group amounted to €3.0 million (as of 30 June 2012: €3.4 million)

- EBITDA fell to €-0.636 million in the second quarter of 2013 compared to €0.615 million in the same period of the previous year. In the first half of the year overall, EBITDA deteriorated from €1.161 million in 2012 to €-0.288 million in 2013.

- In the second quarter of 2013, the consolidated net result after interest and taxes declined by €1.266 million from €0.235 million in the same quarter of the previous year to €-1.031 million. For the period between 1 January and 30 June, the consolidated net result after interest and taxes declined by €1.454 million from €0.387 million in 2012 to €-1.067 million in 2013.

- Earnings per share fell in the second quarter from €0.04 in 2012 to €-0.19 in 2013. In the first half of the year overall, earnings per share dropped from €0.07 in 2012 to €-0.20 in 2013.

- In the first six months of the 2013 financial year, cash flow from operating activities decreased from €-0.089 million in the first half of the previous year to €-0.195 million.

- As of 30 June 2013, there were 231 full-time equivalents (as of 30 June 2012, 231 employees worked in the Group).

Key figures of the Alphaform Group

T€, exept employees and earnings per share	Quarter 2			1 January - 30 June		
	2013	2012	Change in %	2013	2012	Change in %
Revenue	6.041	7.329	-17,6	12.608	14.083	-10,5
EBITDA	-636	615	-203,4	-288	1.161	-124,8
Operating result	-945	289	-427,0	-892	508	-275,6
Result after tax	**-1031**	**235**	**-538,7**	**-1.067**	**387**	**-375,7**
Earning per share	-0,19	0,04	-575,0	-0,20	0,07	-385,7
Equity as of June 30 (2012 as of Dec, 31)				11.722	12.782	-8,3
Total assets as of June 30 (2012 as of Dec, 31)				20.263	21.385	-5,2
Equity ratio (percent)				57,8	59,8	-3,2
Cash and cash equivalents and securities as of June 30 (2012 as of Dec, 31)				896	1.633	-45,1
Group employees as of June, 30				231	231	0,0

Interim group management report

Company development / sector overview

Low demand in the final quarter of 2012 caused market prices in the 3D Printing and Additive Manufacturing Division (formerly Prototyping) to sink throughout the entire first quarter of 2013. We were forced to accept these prices in order to retain our major customers and gain new project orders despite high levels of customer restraint. Although we witnessed this development, we were surprised by the extent of the accumulated losses of income at the end of the second quarter. The automotive business is influenced above all by demand from German manufacturers, which are currently advancing numerous new developments, primarily in the premium segment and for electric cars. Our 3D Printing and Additive Manufacturing Division has been benefiting from this since the second quarter of 2011. After the above-mentioned drop in orders, the division has posted increasing orders again since March 2013. The order backlog has now even returned to a satisfactory level. Nevertheless, the division lost €0.6 million in revenue year-on-year, going from €8.5 million in the first half of 2012 to €7.9 million in the reporting period. Demand for laser sintering and stereolithography is growing. We have therefore expanded production at two 3D printing locations; additional laser-sintering and stereolithography systems for the manufacture of complex metal and plastic parts went into operation here over the course of the year.

The Alphaform Medical Division (formerly MediMet and Alphaform-Claho) also had to cope with a considerable decline in demand. A central reason for this was the reduction of stock by our customers. Last year, some of them built up considerable safety stocks that have now been liquidated. As a result, we occasionally had to grant price concessions in order to obtain orders, which more than ate up the gains in efficiency we still made. Recovery did not set in until the middle of the second quarter and continues to this day. Overall, revenue in the Medical Division decreased by €0.8 million in the first half of 2013 from €5.5 million in the previous year to €4.7 million in the current reporting period. Because demand for orthopaedic implants has generally remained intact, we expect stable development over the rest of the year. We are therefore confident of keeping the Medical Division at least at break-even point over the course of the year. In the near future, our new laser-sintering pilot plant in Eschenlohe for additive manufacturing of metal implants could provide additional positive revenue stimuli.

The development of the foreign subsidiaries in Scandinavia and the UK remained on the up, although here, too, the strong growth of recent years seems to be at an end. In the first half of 2013, the companies achieved slight profitable growth on the same period of the previous year, totalling 2.0% over all activities.

In line with the poor business development, EBITDA fell to €-0.636 million in the second quarter of 2013 compared to €0.615 million in the same period of the previous year. In the first half of the year overall, EBITDA deteriorated from €1.161 million in the previous year to €-0.288 million in the reporting period. In the first half of 2013, the gross profit margin decreased by 7.7% from 71.7% in the previous year to 63.3% now. This is due to year-on-year price reductions of around 10% throughout the company, which were only partially absorbed by our efficiency improvement measures.

Net assets, financial position and results of operations

Revenue development and order situation

Compared with the same period of the previous year, consolidated revenue fell by 10.5% to €12.608 million, starting at €14.083 in the first six months of 2012.

The order backlog amounted to €3.0 million at the end of the second quarter of 2013. The order backlog therefore fell 11.8% compared to the same date of the previous year (order backlog as 30 June 2012: €3.4 million).

Material costs and gross profit margin

In the second quarter of 2013, the gross profit margin generated was 63.3%, 7.7% lower than in the same period of 2012 (71.0%).

In the second quarter of 2013, material costs fell by €0.150 million from €2.364 million in 2012 to €2.214 million.

Results of operations

The net result of the Alphaform Group deteriorated by €1.266 million in the second quarter of 2013 compared to the same period of the previous year, from €0.235 million in the second quarter of 2012 to €-1.031 million in the second quarter of 2013.

Staff costs

Staff costs decreased by €0.163 million in the second quarter of 2013 compared to the same period of the previous year, which equates to a reduction of 5.8%.

Depreciation, amortisation and impairment

Depreciation and amortisation fell slightly in the second quarter of 2013 compared to the same period of the previous year. In the second quarter of 2013, depreciation and amortisation amounted to €0.309 and were therefore 5.5% lower than in the second quarter of 2012 (€0.326 million).

Other operating expenses

At €1.527 million in the second quarter of 2013, other operating expenses were €0.251 million lower than in the same period of the previous year (€1.778 million). This is mainly due to savings in costs for premises.

Financing and cash flow

The Group's cash flow statement shows the origins and use of the cash flow in the first six months of the financial years 2013 and 2012. Cash flows are divided into those from current operating activity and those from investing and financing activities.

In the second quarter of 2013, cash flow from operating activity was €-0.195 million, €0.106 million less than the cash flow of €-0.089 million in the same period of the previous year. The main reason for the lower cash flow compared to the same period of the previous year was the poorer earnings development.

In the second quarter of 2013, cash outflow from investing activity amounted to €0.487 million, with the majority resulting from the acquisition of property, plant and equipment.

Cash flow from financing activity was neutral. In the same period of the previous year, there was cash outflow of €0.338 million due to the repayment of bank loans.

Cash and cash equivalents decreased by €0.246 million compared to the same period of the previous year. On 30 June 2013, available cash and cash equivalents amounted to €0.896 million compared to €1.142 million as of 30 June 2012.

Statement of financial position

As of 30 June 2013, total assets amounted to €20.263 million and had decreased by €1.122 million compared to the carrying amount as of 31 December 2012 (€21.385 million). The equity ratio fell from 59.8% as of 31 December 2012 to 57.8% as of 30 June 2013.

The biggest changes compared to the end of 2012 relate to the items ‘bank balances’ and ‘receivables’. Bank balances decreased by €0.737 million from €1.733 million as of 31 December 2012 to €0.996 million as of 30 June 2013. Receivables fell by €0.913 million from €3.526 million as of 31 December 2012 to €2.613 million as of 30 June 2013. This is mainly due to lower revenue.

Employees

On 30 June 2013, our company employed 231 full-time equivalents. This is the same number of employees as on the same date of the previous year. At present, the Alphaform Group employs seven trainees.

As of 30 June 2013 and 30 June 2012, the employee structure was as follows:

	Quarter 2		
	2013	**2012**	**Change in %**
Alphaform AG	90	80	12,5
Alphaform-Claho GmbH	39	40	-2,5
Alphaform RPI Oy, Finland	16	16	0,0
Alphaform Ltd., United Kingdom	2	2	0,0
Alphaform-Projekt GmbH	0	0	0,0
MediMet GmbH	84	93	-9,7
Employees Group total	**231**	**231**	0,0

Risk and forecast report

The Alphaform Group generates a significant proportion of its revenue with project orders from the automotive industry and serial orders for medical orthopaedics. These industries in particular are characterised by persistent pressure on suppliers, aggressive price competition, tight development budgets and shorter project terms. In addition, the development landscape of the automotive industry is changing. As it is not always possible for us to predict these processes, they represent a significant risk for the full utilisation of our capacities and hence for our results. Furthermore, consolidation trends are being observed among major market players (OEMs) in the medical technology area, which also entail the risk of increasing price pressure in the supplier sector.

Outlook

For the remainder of the financial year, we expect the overall situation, which has already improved considerably in recent weeks, to stabilise at least. This is also supported by the current forecasts for general economic growth, most of which predict total growth of between 0.2% and 0.6% for Germany despite the weak start to the year. Our customers in the automotive sector, which operate predominantly in the premium segment, can more than make up for the sales lull in Europe with their global presence. They are also benefiting from the weakness of the euro. Demand for medical implants, which was temporarily very weak, has now also recovered – and stable further development is also expected here thanks to intact drivers. We also see these generally expected trends towards stabilisation reflected in our business performance. However, the disappointing first half of the year with its losses in revenue and the price slump compels us to revise downwards our current forecast for the 2013 financial year. We now expect revenue of €26.5 million and a slightly negative net result after taxes compared with the revenue of €27 million to €29 million and net result after taxes of €0.8 million previously forecast. This revised forecast refers exclusively to existing business and economic development; speculative upward impetus from new business fields and technology such as 3D printing or laser-sintered implants was not included.

Feldkirchen, 9 August 2013

Dr Thomas Vetter
CEO of Alphaform AG

Group – Consolidated statement of comprehensive income

In T€, with the exception of earnings per share and number of shares		Quarter 2		1 January - 30 June	
		2013	**2012**	**2013**	**2012**
Revenues	19	6.041	7.329	12.608	14.083
Changes in inventories		-304	-95	-258	-29
Other operating income		19	337	115	544
Cost of materials	19	-2.214	-2.364	-4.487	-4.498
Gross profit		**3.542**	**5.207**	**7.978**	**10.100**
Personnel expenses	19	-2.651	-2.814	-5.337	-5.529
Depreciation and amortisation costs and other write-offs	19	-309	-326	-604	-653
Other operating expenses	19	-1.527	-1.778	-2.929	-3.410
Operating result		**-945**	**289**	**-892**	**508**
Other interest and similar income	19	1	3	1	7
Interest and similar expenses	19	-87	-55	-175	-124
Result before tax		**-1.031**	**237**	**-1.066**	**391**
Other taxes	13	0	-2	-1	-4
Result after tax	19	**-1.031**	**235**	**-1.067**	**387**
Allocations of profit or loss					
profit or loss attributable to minority interest		**6**	**0**	**7**	**1**
Gross profit / loss		**-1.025**	**235**	**-1.060**	**388**
Profit/loss per share					
Profit/loss per share (basic)		-0,19	0,04	-0,20	0,07
Profit/loss per share (diluted)		-0,19	0,04	-0,20	0,07
Weighted average number of shares outstanding (basic)		5.318.209	5.318.209	5.318.209	5.318.209
Weighted average number of shares outstanding (diluted)		5.318.209	5.318.209	5.318.209	5.318.209

Group – Statement of financial position

T€	30 June 2013	31 December 2012
Assets		
Cash and cash Equivalents	996	1.733
free cash	896	1.633
resticted cash	100	100
Trade accounts receivable	2.613	3.526
Inventories	4.506	4.593
Other current assets	1.736	958
Total current assets	9.851	10.810
Property and equipment, net	4.134	4.193
Intangible assets, net	5.377	5.430
Cash and cash Equivalents	886	932
resticted cash	886	932
Deferred Tax asset	11	12
Other non-current assets	4	8
Total noncurrent assets	10.412	10.575
Total Assets	**20.263**	**21.385**

T€	30 June 2013	31 December 2012
Liabilities and shareholders' equity		
Common stock, € 1 par value	5.318	5.318
Additional paid-in capital	11.325	11.325
Accumulated other comprehensive loss	7	0
Accumulated profit/loss	-4.928	-3.861
Total shareholders' equity	11.722	12.782
Noncurrent liabilities		
Liabilities due to banks	681	804
Other liabilities	1.134	1.207
Finance lease obligations	344	454
Current liabilities		
Current finance lease obligations	229	235
Liabilities due to banks	1.136	898
Trade accounts payable	2.736	2.428
Other provisions/liabilities	2.281	2.577
Total liabilities	8.541	8.603
Total liabilities and shareholders' equity	**20.263**	**21.385**

2012 and 2013: 5,318,209 shares per € 1 par value

2012 and 2013 authorised capital stock € 2,659,104, 2012 and 2013 conditional capital €531,820

Group – Consolidated statement of cash flows

	1 January - 30 June	
	2013	**2012**
T€		
Result after taxes	-1.067	387
Adjustments reconcile net profit/loss to net cash from/used in operating activities		
Depreciation of property, plant and equipment	546	653
Depreciation of intangible assets	57	0
Sale of property, plant and equipment at residual value	0	130
Currency translation differences	7	-12
Changes in operating assets and liabilities:		
Trade receivables	913	-666
Inventories	87	-113
Other current assets	-778	104
Restricted cash	100	-154
Liabilities	308	27
Other provisions and liabilities	-369	-445
Net cash from operating activities	**-195**	**-89**
Acquisition of property, plant and equipment, excl. finance leases	-487	-515
Proceeds from the sale of property, plant and equipment, excl. finance leases	0	0
Expenses for other loans	0	7
Acquisition of subsidiaries	0	-75
Net cash used in investing activities	**-487**	**-583**
New Bank Loans	238	478
Principal payments on bank loans	-123	-737
Principals payments under finance leases	-116	-79
Net cash used in financing activities	**-1**	**-338**
Net reduction in cash and cash equivalents	-683	-1.010
Restricted cash	-54	600
Cash, cash equivalents and short term investments at beginning of period	1.633	1.552
Cash and cash equivalents includung short-term investments at the end of the period	**896**	**1.142**
Additional cash flow statement disclosures		
Cash paid for interest	175	124
Revenue for interest	1	7
Non-cash transactions:		
Property, plant and equipment acquired under finance leases	0	376

Group – Consolidated statement of changes in equity

All figures in € thousand exept number of shares	Common Stock: Number of shares	Common Stock: Amount	Additional paid-in-capital	Accumulated other comprehensive income	Accumulated profit / deficit	Total shareholders´ equity
IAS/IFRS shareholders´equity as of December 31, 2011	**5.318.209**	**5.318**	**11.325**	**9**	**(4.398)**	**12.254**
Result					387	387
Foreign currency translation				(10)		(10)
IAS/IFRS shareholders´equity as of June 30, 2012	**5.318.209**	**5.318**	**11.325**	**(1)**	**(4.011)**	**12.631**
IAS/IFRS shareholders´equity as of December 31, 2012	**5.318.209**	**5.318**	**11.325**	**0**	**(3.861)**	**12.782**
Result					(1.067)	(1.067)
Foreign currency translation				7		7
IAS/IFRS shareholders´equity as of June 30, 2013	**5.318.209**	**5.318**	**11.325**	**7**	**(4.928)**	**11.722**

Notes to the consolidated financial statements (condensed)

Basis of consolidation

The consolidated financial statements include Alphaform AG and all its affiliated companies in accordance with the method of full consolidation. In the second quarter of 2013, there was no change in the Group compared to the status as of 31 December 2012.

As of 30 June, the company directly held 100% of the shares in the following subsidiaries:

- Alphaform-Projekt GmbH, Feldkirchen 100%
- Alphaform Ltd., Newbury, UK 100%
- Alphaform-Claho GmbH, Eschenlohe 100%
- Alphaform RPI Oy, Rusko, Finland 100%
- MediMet Precision Casting and Implants Technology GmbH 100%

Basic accounting policies

Principles of reporting

The present report as of 30 June 2013 was prepared in condensed form compared to the consolidated annual financial statements in accordance with the regulations of IAS 34 “Interim Financial Reporting”.

The consolidated financial statements as of 31 December 2012 were prepared in accordance with the International Financial Reporting Standards (IFRS) of the International Accounting Standards Board (IASB) considering the interpretations of the International Financial Reporting Interpretations Committee (IFRIC).

The accounting and consolidation policies applied in this report as of 30 June 2013 are the same as those used in the consolidated financial statements as of 31 December 2012.

The accounting policies were applied consistently to all financial years presented in the financial statements. Expenses and incomes that are not usually incurred until the end of the financial year are recognised by period for the purposes of interim financial reporting.

Further, the recommendations of Deutsche Börse on quarterly reporting by companies listed in the Prime Standard are also applied.

The interim consolidated financial statements were neither audited in line with section 317 of the German Commercial Code (HGB) nor reviewed by an auditor.

The same principles of consolidation were applied in preparing the interim financial statements and calculating comparative figures as for the 2012 consolidated financial statements.

Segment reporting

A business segment is a distinguishable component of a group that is engaged in providing products or services and that is subject to risks and returns that are different from those of other business segments.

Segment information is provided on the Group’s business and geographical segments. The basis for the primary segment reporting format is the Group's management structure and its internal financial reporting system. Segment results contain components that are directly attributable to the individual segment or that can be reasonably allocated to the segments.

Business segments

The Group consists primarily of the following two business segments:

Additive Manufacturing/3D Printing

The Additive Manufacturing/3D Printing business segment comprises Alphaform AG, Feldkirchen (including Group Administration), Alphaform RPI Oy, Finland, Alphaform Ltd., UK and Alphaform-Projekt GmbH, Feldkirchen.

Medical Division

The Medical Division business segment comprises Alphaform-Claho GmbH, Eschenlohe, and MediMet GmbH, Stade.

Period from 1 January to 30 June 2013:

T€	AM / 3DPrinting 2013	Medical Devision 2013	Not allocated 2013	Group 2013
External revenues	7.871	4.737	0	12.608
Revenues with other segments	7	477	-484	0
Revenues	**7.878**	**5.214**	**-484**	**12.608**
Segment earnings	**-589**	**-310**	**7**	**-892**
Interest income	17	1	-17	1
Interest expense	-134	-58	17	-175
Other expenses, net	0	0	0	0
Profit/loss before taxes	**-706**	**-367**	**7**	**-1.066**
Income taxes	0	-1	0	-1
Net result for the period	**-706**	**-368**	**7**	**-1.067**

Period from 1 January to 30 June 2012:

T€	AM / 3DPrinting 2012	Medical Devision 2012	Not allocated 2012	Group 2012
External revenues	8.547	5.536	0	14.083
Revenues with other segments	4	658	-662	0
Revenues	**8.551**	**6.194**	**-662**	**14.083**
Segment earnings	**258**	**250**	**0**	**508**
Interest income	33	1	-27	7
Interest expense	-86	-65	27	-124
Other expenses, net	0	0	0	0
Profit/loss before taxes	**205**	**186**	**0**	**391**
Income taxes	0	-4	0	-4
Net result for the period	**205**	**182**	**0**	**387**

Geographical segments

The geographical segments are divided into Central Europe and Northern Europe. Segment revenue information is presented on the basis of the domicile of the respective customer.

The following table shows the geographical distribution of revenue:

Consolidated revenue from 1 January to 30 June:

Group revenues	Central Europe		Northern Europe		not allocated		Total	
T€	2013	2012	2013	2012	2013	2012	2013	2012
Germany	6.377	7.095	0	1	0	0	6.377	7.096
Finland	15	0	1.045	1.180	0	0	1.060	1.180
UK	87	88	1.452	1.199	0	0	1.539	1.287
Rest of Europe	921	1.320	0	0	0	0	921	1.320
Rest of World	2.711	3.200	0	0	0	0	2.711	3.200
Total	**10.111**	**11.703**	**2.497**	**2.380**	**0**	**0**	**12.608**	**14.083**

Stock option plans

No stock options were issued to the Management Board or the Supervisory Board in 2013 or 2012.

Related parties

There were no personnel changes in the Management Board or Supervisory Board in the second quarter of 2013.

The following table shows the shareholdings of the Management Board and the Supervisory Board as of 30 June 2013:

	Position	Stock options as of 30 June 2013	Shares as of 30 June 2013	Per cent of share capital 1)
Dr. Thomas Vetter	Chief Executive Officer		125.321 2)	2.36
Matti Paasila	Chairman of the Supervisory Board		60.000	1.13
Dr. Hans J. Langer	Member of the Supervisory Board		976.659 3)	18.36
Falk F. Strascheg	Member of the Supervisory Board		852.317 4)	16.03
Total		**0.00**	**2.014.297**	**37.88**

1) 5.318.209 shares
2) of which 53.180 shares held by Juana Parra
3) of which 976.659 shares held by LHUM Vermögensverwaltungs GmbH
4) of which 433.583 shares held in Renate Strascheg Holding GmbH;
of which 418.734 shares in Falk Strascheg Holding GmbH

As of 30 June 2013, no stock options had been issued to members of the Management Board or the Supervisory Board. The company has not granted any loans to members of the Management Board or Supervisory Board. However, Alphaform AG has taken on a bank guarantee at the bank Donner & Reuschel, Munich, for a loan to Dr Vetter in the amount of €400 thousand.

Effective from 1 February 2010, there is a consulting agreement between Alphaform AG and Mr Matti Paasila independently of his position as the Chairman of the Supervisory Board of Alphaform AG. Mr Paasila supports the company in the implementation of its strategic reorientation with his particular expertise and his access to an international network on approximately 10-15 compensated consulting days per year, for a daily fee of €1.5 thousand. In particular, Mr Paasila plays an active role generating leads, analysing and assessing companies (due diligence) and negotiating purchase prices. Mr Paasila also advises the company on the operational integration of acquired companies into the Alphaform Group.

Other than this, there are currently no further consulting contracts with current or former members of the Supervisory Board.

As a member of the Supervisory Board of Alphaform AG, Dr Hans Langer is also the Chairman of the Management Board of EOS Holding AG in Krailling. EOS GmbH, a wholly owned subsidiary of EOS Holding AG, is one of Alphaform AG's largest suppliers of raw materials with a purchasing volume of €0.4 million in the first six months of 2013 (previous year: €0.4 million).

Events after the first six months

After the first six months of 2013, there were no further events of essential importance to Alphaform or that could require a changed assessment of the company.

Financial calendar 2013:

Publication of the Interim Report Q3 2013
Date: 8 November 2013

Eigenkapitalforum – Offer of individual meetings with the CEO for investors
Date: 11 + 12 November 2013

Investor Relations

E-Mail: ir@alphaform.de
Tel: + 49 89 90 500 2-35
Fax: + 49 89 90 500 2-1035

Alphaform AG
Kapellenstrasse 10
85622 Feldkirchen
Germany

This report can be downloaded from the Internet in English and German.